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Highlights 
1. What is already known about this topic? 
Indirect bronchoprovocation testing, specifically eucapnic voluntary hyperpnoea (EVH) is 
currently recommended for the diagnosis of exercise-induced bronchoconstriction (EIB). 
However the clinical reproducibility of this methodology has yet to be appropriately 
established; presenting a potential for misdiagnosis.  
 
2. What does this article add to our knowledge?  
This article highlights the need for caution when making a diagnosis of EIB based on a 
solitary EVH assessment to reduce the potential for misdiagnosis. Indeed when encountering 
patients with a mild or borderline reduction in lung function post challenge, we recommend 
that more than one EVH test is performed to exclude or confirm a diagnosis of EIB.  
 
3. How does this study impact current management guidelines? 
The application of treatment for EIB in recreational athletes should only be initiated when a 
diagnosis has been correctly established.  
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ABSTRACT   
Background: In athletic individuals, a secure diagnosis of exercise-induced 
bronchoconstriction (EIB) is dependent upon objective testing. Indirect bronchoprovocation 
testing is often employed in this context and eucapnic voluntary hyperpnea (EVH) testing is 
recommended for this purpose, yet the short-term reproducibility of EVH has yet to be 
appropriately established. Objective: The aim of this study was to evaluate the 
reproducibility of EVH in a cohort of recreational athletes. Methods: A cohort of recreational 
athletes (n = 32) attended the laboratory on two occasions to complete an EVH challenge, 
separated by a period of 14 or 21 days. Spirometry and impulse oscillometry (IOS) was 
performed before and following EVH. Training load was maintained between visits. Results: 
Pre-challenge lung function was similar at both visits (P>0.05). No significant difference was 
observed in maximum change in FEV1 (∆FEV1max) post EVH between visits (P>0.05) and 
test-retest ∆FEV1max was correlated (ICC = 0.81; r2 = 0.66; P = 0.001). Poor diagnostic 
reliability was observed between tests; eleven athletes were diagnosed with EIB (based on 
∆FEV1max ≥10%) at visit 1 and at visit 2. However, only seven athletes were positive at both 
visits. Whilst there was a small mean difference in ∆FEV1max between tests (-0.6%) there 
were wide limits of agreement (-10.7 – 9.5%). Likewise, similar results were observed for 
IOS between visits. Conclusion: In a cohort of recreational athletes, EVH demonstrated poor 
clinical reproducibility for the diagnosis of EIB. These findings highlight a need for caution 
when confirming or refuting EIB based on a single indirect bronchoprovocation challenge. 
When encountering patients with mild or borderline EIB, we recommend that more than one 
EVH test is performed to exclude or confirm a diagnosis.  
Key words: Airway dysfunction, Athletes, Eucapnic voluntary hyperpnea, Exercise-induced 
bronchoconstriction, Indirect bronchoprovocation testing, Reproducibility.  
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ABBREVIATION LIST 
AQUA  Allergy Questionnaire for Athletes 
AUC   Area under the curve 
AX   Area of reactance (area integrated from 5Hz to RF) 
BMI  Body mass index 
CO2   Carbon dioxide 
EIB  Exercise-induced bronchoconstriction  
EVH   Eucapnic voluntary hyperpnea 
FEV1   Forced expiratory volume in one second.  
FVC  Forced vital capacity 
ICC   Intra-class correlation 
IOC-MC  International Olympic Committee-Medical commission 
IOS   Impulse oscillometry  
LOA   Limits of agreement 
MVV   Maximal voluntary ventilation 
N2   Nitrogen 
O2   Oxygen 
R   Resistance 
R5   Resistance at 5 Hz 
R20   Resistance at 20 Hz 
RF   Resonance frequency 
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SABA  Short acting beta-2 agonist 
SD  Standard deviation 
X   Reactance 
Z   Impedance 
Z5   Magnitude of impedance at 5 Hz  
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INTRODUCTION 
Exercise-induced bronchoconstriction (EIB) describes the transient airway narrowing that 
occurs in association with exercise. It is prevalent in both elite and recreational athletes (1) 
and may impact upon both their respiratory health and athletic performance (2-4). It is now 
well established that the diagnosis of EIB in athletes should not be based on clinical 
assessment alone (5-7) since a poor correlation exists between exercise-related symptoms and 
objective evidence of airway narrowing (8). As a consequence of this dissociation, current 
guidelines recommend that objective bronchoprovocation testing is employed to secure a 
diagnosis of EIB (9, 10).  
Exercise testing is frequently employed to diagnose EIB. However, whilst an exercise test is 
ecologically valid and possesses good specificity for diagnosis, it has poor sensitivity and is 
limited by difficulties in controlling environmental conditions and exercise load and thus, the 
airway stimulus during a challenge (11). Indeed, poor short-term reproducibility of a 
laboratory exercise test for the diagnosis of EIB in a non-athletic group has previously been 
observed, with the conclusion that one test may not be enough to secure a diagnosis (12). 
Several ‘indirect’ airway challenges have been developed and recommended as surrogate 
means for diagnosing EIB. The International Olympic Committee-Medical Commission 
(IOC-MC) (13) and several other guideline committees strongly endorse the eucapnic 
voluntary hyperpnea (EVH) challenge in this capacity (9, 10). The EVH challenge uses a 
compressed, dry gas as the stimulus for provoking bronchoconstriction with controlled 
hyperpnea.  
The EVH test has been used and recommended for screening athletic cohorts for EIB (14, 15); 
with a positive ‘diagnosis’ being made from a single provocation test. However, there is 
sparse data regarding the reproducibility of EVH (16, 17) and the inherent variability in any 
test has pragmatic implications for evaluating the effectiveness of a diagnostic tool in 
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screening programmes and interventions. Moreover, the reliability of EVH testing in the 
population of athletes in whom EVH screening has been advocated (i.e. team squads (15, 18) 
at amateur or varsity level) has not been established. In this population, the fall in FEV1 post-
challenge can often be borderline (i.e. 10-15% fall) and thus it is important to determine the 
stability and thus precision of such a result. 
We therefore undertook this study with the aim of evaluating the test-retest reproducibility of 
EVH in a cohort of recreational athletes. We proposed that there would be no difference in 
airway response following EVH between visits; i.e. EVH would have good test-retest 
reproducibility. A secondary aim was to evaluate the reproducibility of measures of small 
airway function utilising impulse oscillometry (IOS) over the same period of time.  
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MATERIALS AND METHODS 
Study population 
Thirty-six recreational athletes (training 6 ± 1 hours / week) (male: n = 31) from a variety of 
sporting disciplines; endurance (n = 22) (runners, cyclists and triathletes), intermittent high-
intensity (n = 11) (soccer, rugby and hockey), and non-endurance (n = 3) (weightlifters) were 
recruited to take part in the study. All subjects were non-smokers, free from respiratory, 
cardiovascular, metabolic and psychiatric disease, and any other significant medical condition 
except mild asthma. Six subjects had a physician-based diagnosis of mild asthma; all were 
prescribed a short acting beta-2 agonist (SABA) and two prescribed a regular inhaled 
corticosteroid.  
Experimental design 
All subjects were required to attend the laboratory on two occasions separated by a period of 
either 14 or 21 days. Subjects entered the laboratory 1-hr postprandial at a similar (± 1 h) time 
of day for each visit. An assessment of respiratory health and evaluation of allergy status was 
determined via completion of the Allergy Questionnaire for Athletes (AQUA) and 
aeroallergen skin prick testing. Spirometry and impulse oscillometry (IOS) manoeuvres were 
performed pre and post an EVH provocation challenge (described below). 
Subjects were instructed to maintain their normal diet and physical activity levels throughout 
the duration of the study and compliance with this regime was assessed by interview. 
Exclusion occurred if any alteration in training and/or health status/allergen exposure or 
respiratory tract infection was reported. Subjects were asked to abstain from strenuous 
physical activity and SABA medication for 24 hrs and inhaled corticosteroid for 72 hrs, 
respectively, prior to each laboratory visit. All tests and procedures were approved by the 
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local research ethics committee and all subjects provided written informed consent for 
experimentation with human subjects. 
Atopic Status 
Sensitivity to seven common airborne allergens (early blossom tree, mid blossom tree, grass, 
weed, mould, cat and dust mite) were assessed via skin prick testing (19). Subjects also 
completed AQUA to assess allergic symptoms (20). An athlete was considered to be allergic 
if they presented with a positive skin prick test and a positive AQUA score ≥5. 
Pulmonary function 
Spirometry 
Lung function was assessed by forced flow-volume spirometry (MicroLoop ML3535; 
Cardinal Health, UK) (21). Subjects with airway obstruction at visit 1 (FEV1/FVC <0.7; FEV1 
% predicted <0.8) were excluded.  
Eucapnic voluntary hyperpnea 
A modified version of EVH was performed based on the protocol described previously (17, 
22). Briefly, subjects breathed a dry compressed gas mixture (21% O2, 5% CO2, balance N2) 
at a target ventilation rate equivalent to 85% (baseline FEV1*30) of their predicted maximal 
voluntary ventilation (MVV) for 6 min. Subjects received real-time visual feedback of their 
ventilation in order to ensure they maintained the target level. Spirometry was performed in 
triplicate at baseline and in duplicate at 3, 5, 7, 10 and 15-minute post EVH. Values within 
5% were considered acceptable (21). The highest recorded value at each time point was used 
for analysis. A positive diagnosis for EIB was defined by a fall in FEV1 of ≥10% at two 
consecutive time points following the EVH challenge in accordance with IOC-MC 
recommendations (13). Severity of EIB was classified according to the magnitude of 
reduction in FEV1; mild (≥10% - <25%), moderate (≥25% - <50%) or severe (≥50%).  
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Impulse oscillometry technique 
Impulse oscillometry measures were obtained (MasterLab IOS System (Erich Jaeger Co., 
Wurzburg, Germany), in accordance with international recommendations (23), prior to 
spirometry, immediately pre and post EVH. In brief, subjects performed 30 s of tidal 
breathing prior to a maximal inspiratory manoeuvre followed by a passive expiratory 
manoeuvre. 
Statistical analysis 
It was calculated that a sample size of thirty-two subjects would provide statistical power 
above 80%, with an alpha level of 0.05. Normally distributed data are expressed as mean (± 
SD) or 95% confidence intervals (CI). Significance was set at P < 0.05. A two-sided paired t-
test was used to evaluate differences in variables between visits. Pearson’s intra-class 
correlation coefficient (ICC) was calculated using a two-way mixed effect model with the 
mean single measure reported; ICC ranges from -1 to +1; the latter indicating perfect 
agreement. Reproducibility was assessed using the method described by Bland and Altman 
(24) with difference expressed as mean bias (i.e. mean difference between group measures) 
and upper and lower 95% limits of agreement (LOA). AUC0-15min was calculated by the 
trapezoidal method and expressed as percentage fall in FEV1. Data was analysed using PASW 
Statistics 19 statistical software package (SPSS Inc., Version 19, Chicago, IL) and GraphPad 
Prism Version 5.0 (GraphPad Software, San Diego, California, USA). 
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RESULTS 
Thirty-two athletes (male: n = 28) completed the study. One athlete was excluded at the initial 
visit on the basis of resting airway obstruction and three athletes were excluded due to illness. 
Subjects’ characteristics are presented in Table 1.  
Baseline characteristics and pre-challenge lung function 
Eighteen athletes (56%) were atopic to skin prick tests and eighteen (56%) had a positive (≥5) 
AQUA questionnaire. Thirteen athletes (41%) with a positive AQUA questionnaire were also 
atopic and therefore considered allergic. Exercise associated respiratory symptoms (e.g. 
cough, wheeze, dyspnea etc.) were reported by ten athletes (31%).  
At baseline, all pulmonary function measures were within normal predicted limits with no 
evidence of airflow obstruction (Table 2). Resting spirometric variables were similar between 
visits except for FEV1/FVC (P < 0.01). All IOS measures were similar between visits.  
Short-term reproducibility (n = 32) 
Similar ventilation rates were achieved at both visits (visit 1: 113 ± 25 L.min-1; visit 2: 119 ± 
25 L.min-1) (P = 0.08). Target ventilation was achieved at visit 1 (84.6%) and visit 2 (90.4%) 
respectively. Eleven athletes (34% of cohort) were diagnosed with EIB at visit 1 (mild: n = 
10; moderate: n = 1) and eleven athletes at visit 2 (mild: n = 9; moderate: n = 2). Seven 
athletes were positive at visit 1 and visit 2 (endurance athletes n = 5; intermittent high-
intensity athletes n = 1; non-endurance athletes n = 1). Seventeen subjects (75%) were 
negative on both occasions. 
In those with a previous physician diagnosis of asthma (n = 6), four (66%) were positive at 
visit 1 (mild: n = 3; moderate n = 1) and three (50%) at visit 2 (mild: n = 2; moderate: n = 1). 
Two were positive on both occasions (mild: n = 1; moderate n = 1). A diagnosis of asthma 
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therefore provided a positive and negative predictive value of 33% and 94% respectively, for 
the diagnosis of EIB at either visit. 
Eight athletes with allergy (25%) were positive at visit 1 and six (19%) were positive at visit 
2. Four athletes with allergy (13%) were positive on both occasions. Allergy therefore 
provided a positive and negative predictive value of 67% and 82% respectively, for the 
diagnosis of EIB at either visit.  
No difference was observed in maximum change in FEV1 (∆FEV1max) post EVH between 
visits (visit 1: -9.8%; visit 2: -10.4%) (P = 0.51) [95% CI: 6.5-7.8] and test-retest ∆FEV1max 
was correlated (ICC =0.81; r2 = 0.66; P = 0.001) (Figure 1). Although there was only a small 
bias in ∆FEV1max between tests (-0.6%) the data exhibited wide limits of agreement (-10.7 - 
9.5%) (Figure 2). In addition, no difference was observed for AUC0-15 min % fall in FEV1 
between visit 1 (98.3%) and visit 2 (107.0%) (P = 0.33) (Figure 3) and test-retest was 
correlated (ICC = 0.85; r2 = 0.73; P = 0.001). No difference was observed for resting %FEV1 
predicted between the day of the positive test (98.7 ± 12.2%) and the day of the negative test 
(98.8 ± 14.0%) (P = 0.97). In addition, no difference was observed when both tests were 
either negative (P = 0.66) or positive (P = 0.16). 
Non-asthmatic athletes (n = 26) 
When excluding mild asthmatics from the analysis (n = 6) no difference was observed in 
maximum change in FEV1 (∆FEV1max) post EVH between visits (visit 1: -8.2%; visit 2: -
9.0%) (P = 0.41) [95% CI: 6.3-8.0] and test-retest ∆FEV1max was correlated (ICC = 0.66; r2 
=0.43; P = 0.001). Although there was only a small bias in ∆FEV1max between tests (-0.9%) 
the data exhibited wide limits of agreement (-11.0 - 9.3%). In addition, no difference was 
observed for AUC0-15 min % fall in FEV1 between visit 1 (78.2%) and visit 2 (88.5%) (P = 
0.29) and test-retest was correlated (ICC = 0.73; r2 = 0.53; P = 0.001). 
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Impulse oscillometry (n = 32) 
No difference was observed in any of the IOS variables post EVH between visits (P>0.05) 
(Table 3). Whilst significant correlations were observed between visits for R5 (ICC = 0.89; r2 
= 0.80); R20 (ICC = 0.80; r2 = 0.64); X5 (ICC = 0.62; r2 = 0.39); Z5 (ICC = 0.89; r2 = 0.80); RF 
(ICC = 0.94; r2 = 0.89) and AX (ICC = 0.94; r2 = 0.87) (P = 0.001), all variables exhibited 
wide limits of agreement. 
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DISCUSSION  
In a cohort of recreational athletes, EVH demonstrates poor diagnostic test-retest 
reproducibility over a short-term period of assessment. This finding has implications for the 
clinical utility and application of EVH as a bronchoprovocation challenge in the diagnosis of 
EIB; specifically when it is utilised in a population of recreationally recreational athletes with 
mild reductions in lung function following a challenge. Moreover it highlights the need for 
caution when EVH is employed as a screening tool for EIB in a comparable population.  
Reproducibility is important in characterising the diagnostic utility of a test. A high level of 
short-term, clinically relevant, test-retest reproducibility is vital for clinicians to adopt a 
diagnostic procedure. This is particularly pertinent in the context of EIB where the differential 
diagnosis for exercise-associated dyspnea is broad (25) and several conditions mimic transient 
airflow narrowing, e.g. exercise-induced laryngeal obstruction (26). The implications of over 
and under-diagnosis of EIB in elite athletes have previously been raised (6). For example, a 
false-positive/negative diagnosis has implications on health (e.g. unnecessary medication) and 
performance (e.g. reduced ability) respectively. 
Our findings indicate that whilst there was a good correlation in the change in FEV1 (i.e. fall 
in lung function) between visits, a Bland-Altman plot, which is a clinically relevant 
assessment of reproducibility (24), revealed wide limits of agreement. Specifically, in the 
current study, fifteen athletes (47%) were diagnosed with EIB at either visit 1 (ΔFEV1 -17.9 ± 
9.0%) or visit 2 (ΔFEV1 -19.0 ± 9.6%) but only seven athletes (22%) were diagnosed positive 
at both visits. This was despite strict regulation of training and environmental conditions 
between visits and similar ventilation during the challenge. Therefore when applying a 
threshold of ≥10% fall in FEV1 for the diagnosis of EIB (27) the inherent variability in the test 
between visits raises significant clinical diagnostic implications; particularly in athletes 
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presenting with mild EIB. Indeed, in the small number of athletes (n = 4) with a fall of ≥20% 
in FEV1, their EVH test remained positive at both visits.  
Variability in bronchial responsiveness has been previously observed with direct 
bronchoprovocation challenges (28-30). However as airway hyper-responsiveness to 
pharmacologic agents such as methacholine differ from hyperresponsiveness to exercise or 
osmotic agents (31) and do not infer the presence of inflammatory cells or mediators (32), 
indirect bronchoprovocation challenges such as exercise or surrogate challenges are more 
appropriate for the diagnosis of EIB (33). 
Previous research evaluating EVH indicates good reproducibility in the maximum fall in 
FEV1 following the challenge (16, 17). Argyros and colleagues (17) observed no difference in 
the degree of bronchoconstriction over a 6-week period following EVH. However, the 
magnitude of the fall in FEV1 (-27 ± 11%) was much greater than in the present study (-10 ± 
8%) and they did not calculate limits of agreement. Stadelmann and colleagues (16) 
demonstrated similar findings with limits of agreement at 6% for ΔFEV1 between challenges. 
Although the average reduction in FEV1 was equivalent to the current study, the time interval 
between tests was highly variable and evidence of training load maintenance was not 
reported. Furthermore, as the population consisted of highly competitive swimmers, a unique 
pathophysiological basis to the development of EIB (i.e. airway injury) (34) may be apparent 
and thus differ from the population of the present study. Good reproducibility has previously 
been established for indirect tests such as the dry powder mannitol challenge in asthmatic 
children (35) but this again has not been evaluated in a recreationally athletic cohort. 
In keeping with our findings, recent evidence has highlighted the potential diagnostic pitfalls 
of performing a one-off exercise test for the diagnosis of EIB in subjects with possible asthma 
symptoms. Anderson and colleagues (12) found that 89 of 373 (24%) individuals tested 
positive following an exercise challenge (based on a ≥10% fall in FEV1) at one of two visits. 
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Similar findings were apparent in a study of asthmatics ‘screened’ using a dry gas exercise 
test with a diagnostic cut-off of 15% fall in FEV1 (36). The authors concluded that more than 
one test may be required to exclude or confirm EIB (12). The findings from the present study 
suggest this recommendation with EVH testing.  
The reason for the poor reproducibility is not clear however environmental factors and/or 
physiological variation impacts significantly on variability (37). Airway calibre fluctuates 
throughout the day and over short-term periods (38). Airway hyperresponsiveness in elite 
swimmers assessed by EVH and methacholine has previously been shown to reduce over a 
short-term period as a result of a reduction in training load (34).  
In the current study, no difference was observed in baseline FEV1 and ventilation achieved 
during EVH remained unchanged between visits. Moreover, in those athletes who tested 
positive on only one occasion, no difference was observed in FEV1 on the day of the positive 
versus the negative test.   
A secondary aim of this study was to evaluate the stability of small airway function 
determined by impulse oscillometry (IOS). The latter provides an alternative method for 
measuring and monitoring lung function and is advantageous in that the test is non-effort 
dependent and potentially evaluates small airway function. The technique has previously been 
found to be an acceptable measure to supplement spirometry following EVH (39-41). The 
current study indicates that IOS variables appear to exhibit a similar degree of variability to 
spirometry following EVH, and as such does not support the notion of superiority when 
employed to assess airway calibre in this setting.  
Methodological considerations / future research  
The current study focused on assessing EVH utility in a population of individuals with few 
symptoms, as per AQUA questionnaire assessment. Moreover, the fall in FEV1 post-test was 
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mild with few subjects demonstrating moderate or severe degrees of bronchoconstriction. For 
example, when athletes were positive at only one visit, an average fall in FEV1 of 10.5% 
(range: 4.9 - 19.1%) was observed (i.e. mild). The population of positive individuals could 
therefore be viewed as ‘borderline’ positive for a diagnosis of EIB. Accordingly, the findings 
of the current study are applicable specifically to individuals presenting a mild severity (i.e. 
≥10% - <25% fall in FEV1) reduction in lung function. This population is clinically relevant 
and is frequently reported in screening studies (6, 18, 42, 43), but by the nature of the cut-off 
values are often classified as ‘borderline’ positive.  
The optimum diagnostic ‘cut-off’ for a diagnosis of EIB is not clear. The current value of 
≥10% has been recommended since early use of the test and translated from both asthmatic 
and non-asthmatic populations (17, 22, 44). In the current study, the mean fall in negative 
athletes following EVH was a 5.7 ± 2.5% and thus comparable with prior literature (15). In 
contrast to the proposed bronchodilatory response observed following exercise (45) the 
‘normal’ population mean response to EVH appears to be bronchoconstriction. Indeed, the 
provocative stimulus to the airways during EVH is highly potent and further work is needed 
to determine an appropriate cut-off specifically in endurance athletes who generally achieve 
high ventilation rates.   
Conclusion 
Eucapnic voluntary hyperpnea is currently recommended as a key bronchoprovation 
challenge for the diagnosis of EIB in athletes. This study demonstrates poor diagnostic 
reproducibility over a short-term period of assessment in recreational athletes, when a cut-off 
value ≥10% fall in FEV1 is employed. Accordingly, the findings indicate the need for caution 
when clinicians make a diagnosis based on a solitary EVH assessment and suggest that further 
assessment and/or surveillance is considered. Therefore when encountering patients with a 
mild or borderline reduction in lung function post challenge, we recommend that more than 
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one EVH test is performed to exclude or confirm a diagnosis. This is important to minimise 
the chance of misdiagnosis and thus mistreatment. 
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TABLE HEADINGS 
Table 1: Subject clinical characteristics.  
Definitions of abbreviations: BMI, body mass index; AQUA+, Allergy Questionnaire for 
Athletes (positive scores above ≥5).  
  
Table 2: Baseline pulmonary function.  
Definitions of abbreviations: FEV1, Forced expiratory volume in 1-s; FVC, Forced vital 
capacity; R5, resistance at 5 Hz; R20, resistance at 20 Hz; X5, reactance at 5Hz; Z5, magnitude 
of impedance at 5 Hz; RF, resonance frequency; AX, area of reactance (area integrated from 
5Hz to RF); EVH, eucapnic voluntary hyperpnea.  
 
Table 3: Impulse oscillometry variables post eucapnic voluntary hyperpnoea between visits.  
Definitions of abbreviations: R5, resistance at 5 Hz; R20, resistance at 20 Hz; X5, reactance 
at 5Hz; Z5, magnitude of impedance at 5 Hz; RF, resonance frequency; AX, area of reactance 
(area integrated from 5Hz to RF). 
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  Table 1. 
Variables  
Sex (M:F)  28 : 4 
Age (years)  28 ± 7 
Height (cm)  178.3 ± 6.5 
Weight (kg)  81.4 ± 12.0 
BMI (kgm-2)  25.6 ± 3.3 
Training (hrswk-1)  6 ± 1 
Physician diagnosed asthma  6/32 (19%) 
Self-report symptoms   10/32 (31%) 
AQUA+  18/32 (56%) 
Atopic  18/32 (56%) 
 Data presented as Mean ± SD. n = 32. 
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Table 2.  
 
 
 
 
 
 
 
 
 
 
 
 
Data presented as Mean ± SD. n = 32, **denotes different from visit 1 (P<0.01). 
Baseline pulmonary function  
 Visit 1 Visit 2 
FEV1 (L)  4.45 ± 0.75   4.40 ± 0.76 
FEV1 (% predicted)  101.5 ± 11.8  100.3 ± 12.6 
FVC (L)  5.51 ± 0.83   5.56 ± 0.75 
FVC (% predicted)  105.6 ±  11.9 106.8 ± 10.9 
FEV1/FVC (%)  80.9 ± 6.0 78.99 ± 7.37** 
R5 (kPaL-1s-1)  0.29 ± 0.09   0.27 ± 0.06 
R20 (kPaL-1s-1)       0.25 ± 0.06    0.24 ± 0.05 
X5 (kPaL-1s-1)  -0.10 ± 0.10  -0.08 ± 0.02 
Z5 (kPaL-1s-1)  0.30 ± 0.09   0.29 ± 0.06 
RF (Hz)  11.69 ± 4.44 11.68 ± 3.55  
AX (Hz. kPaL-1s-1)  0.32 ± 0.44   0.25 ± 0.17 
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Table 3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data presented as Mean ± SD. n = 32 
 
Impulse oscillometry variables  
 Visit 1 Visit 2 
R5 (kPaL-1s-1)   0.36 ± 0.11 0.37 ± 0.13 
R20 (kPaL-1s-1)   0.29 ± 0.10 0.27 ± 0.07 
X5 (kPaL-1s-1)     -0.11 ± 0.07    -0.13 ± 0.08 
Z5 (kPaL-1s-1)      0.38 ± 0.12     0.38 ± 0.15 
RF (Hz)    16.15 ± 5.95   16.02 ± 5.98 
AX (Hz. kPaL-1s-1)      0.73 ± 0.87 0.78 ± 1.04 
